References

Epidemiology and treatment of pulmonary arterial hypertension

10.1038/nrcardio.2017.84 · 2017 · External reference

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry

10.1016/j.healun.2020.09.011 · 2020 · External reference

Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial

10.1016/j.healun.2019.09.010 · 2019 · External reference

Phenotypes in pulmonary hypertension

10.1183/13993003.01633-2023 · 2024 · External reference

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

10.1093/eurheartj/ehac237 · 2022 · External reference

Pulmonary hypertension associated with lung diseases

10.1183/13993003.01200-2024 · 2024 · External reference

Pulmonary hypertension in intersititial lung disease: Screening, diagnosis and treatment

10.1097/mcp.0000000000000790 · 2021 · External reference

Definition, classification and diagnosis of pulmonary hypertension

10.1183/13993003.01324-2024 · 2024 · External reference

Pulmonary hypertension in chronic lung disease and hypoxia

10.1183/13993003.01914-2018 · 2019 · External reference

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: Results from the COMPERA registry

10.1183/13993003.01483-2021 · 2021 · External reference

Serial pulmonary hemodynamics in patients with IPFL listed for lung transplantat

10.1164/rccm.202411-2157oc · 2025 · External reference

Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study

10.1111/resp.14378 · 2023 · External reference

Long–term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open–label extension study

10.1183/13993003.02414-2022 · 2023 · External reference

Pulmonary hypertension associated with interstitial lung disease: State–of–the–art review

10.1183/13993003.02651-2025 · 2026 · External reference

Latin American expert opinion paper on the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease

2026 · External reference

Screening for pulmonary hypertension in interstitial lung disease: Preliminary results from the PHINDER study

10.1007/s12325-026-03508-4 · 2026 · External reference

An abbreviated assessment tool for detection of pulmonary hypertension in patients with interstitial lung disease

10.1002/pul2.70316 · 2026 · External reference

Characterization of CT imaging–derived pulmonary vascular abnormalities associated with pulmonary hypertension in chronic lung disease

2026 · External reference

Imaging–based pulmonary hypertension phenotypes in connective tissue disease–related interstitial lung disease

2026 · External reference

On behalf of the pulmonary vascular disease (PVD) section. Pulmonary hypertension associated with interstitial lung diseases

10.1016/j.chest.2025.07.4107 · 2026 · External reference

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis

10.1164/ajrccm.160.2.9810008 · 1999 · External reference

A case of interstitial lung disease–related pulmonary hypertension successfully treated with inhaled iloprost

10.3390/life14091068 · 2024 · External reference

A randomized, double–blind, placebo–controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis

2007 · External reference

Severe pulmonary hypertension–interstitial lung disease presenting as right ventricular failure: Stabilisation with intravenous prostacyclin and maintenance with inhaled prostacyclin

10.1183/23120541.00659-2023 · 2024 · External reference

Inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease: Advances, challenges, and future directions

2026 · External reference

Prognostic factors in pulmonary arterial hypertension: Assessing the course of the disease

10.1183/09059180.00006711 · 2011 · External reference

Comorbidities and survival in patients with chronic hypersensitivity pneumonitis

10.1186/s12931-020-1283-8 · 2020 · External reference

Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results

10.1183/13993003.00172-2024 · 2024 · External reference

Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE–IIP study

10.1016/j.healun.2021.02.006 · 2021 · External reference

Severe pulmonary hypertension in lung disease: Phenotypes and response to treatment

10.1183/13993003.02307-2014 · 2015 · External reference

Hemodynamics and Phosphodiesterase–5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta–Registry Analysis

10.1164/rccm.202412-2371oc · 2025 · External reference

Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: A retrospective cohort study

10.1186/s12890-016-0207-3 · 2016 · External reference

Pulmonary hypertension in rheumatoid arthritis-relation with the duration of the disease

10.1016/j.ijcard.2007.04.084 · 2008 · External reference

Review of the diagnosis and management of pulmonary hypertension associated with interstitial lung disease (ILD-PH)

10.3390/jcm14062029 · 2025 · External reference

Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertension

10.1016/j.resinv.2026.101453 · 2026 · External reference

Prognostic factors in interstitial lung disease-associated pulmonary hypertension: Data from the HYPID cohort and the French Pulmonary Hypertension Registry

10.1183/13993003.02233-2025 · 2026 · External reference